NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENTA shares have increased by 4.5% and is now trading at $55.30. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.73) by $0.43. The biotechnology company had revenue of $27.60 million for the quarter, compared to analysts' expectations of $29.16 million. Enanta Pharmaceuticals had a net margin of 13.46% and a return on equity of 5.04%. Enanta Pharmaceuticals's revenue was down 30.3% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share. View Enanta Pharmaceuticals' earnings history.

6 equities research analysts have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $49.00 to $130.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $71.60 in the next year. This suggests a possible upside of 29.5% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

News stories about ENTA stock have trended very negative on Tuesday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutEnanta Pharmaceuticals.

Enanta Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,600,000 shares, a decrease of 8.6% from the April 30th total of 1,750,000 shares. Based on an average daily trading volume, of 225,700 shares, the short-interest ratio is presently 7.1 days. Approximately 9.1% of the company's stock are short sold. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN) and Deciphera Pharmaceuticals (DCPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Gilead Sciences (GILD), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.21%), State Street Corp (4.56%), Krensavage Asset Management LLC (3.50%), First Manhattan Co. (2.07%), Acadian Asset Management LLC (1.73%) and Deutsche Bank AG (1.32%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Invesco Ltd., First Manhattan Co., AJO LP, AQR Capital Management LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Deutsche Bank AG, Grantham Mayo Van Otterloo & Co. LLC, State Street Corp, International Biotechnology Trust PLC, Aviva PLC, Two Sigma Advisers LP, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $55.30.

Enanta Pharmaceuticals has a market capitalization of $1.11 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]